No insider purchase over the last 90 days. The latest was filed 11 Sept 2025.
Bespoke Extracts, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 1 filing signed by 1 insider.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 1 filing here. Looking back to 2021, when coverage begins, insiders filed 24 purchases and 1 sale.
Insider buying of Bespoke Extracts, Inc. has been absent for the past year.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2024 · cache
25 of 31 declarations
Bespoke Extracts, Inc. is a U.S.-listed microcap trading on the OTCQB under the ticker BSPK; based on the SEC filings reviewed, it is not currently listed on NYSE or NASDAQ. The company is incorporated in Nevada and maintains its corporate headquarters in Aurora, Colorado, United States. Its business profile has changed materially over time: while Bespoke originally had exposure to CBD-oriented products, its current strategy is centered on regulated cannabis markets in the United States, with a stronger emphasis on marijuana-derived consumer packaged goods and production services.
The company traces its origins back to 1988, but the modern cannabis business was effectively launched in 2023 following the acquisition of a state-licensed adult-use marijuana infused products operation in Aurora, Colorado. Through its wholly owned subsidiary, Bespoke Extracts Colorado, LLC, the group operates a marijuana-infused products manufacturing facility. Since that acquisition, Bespoke has expanded into pre-roll production and related contract manufacturing, positioning itself around a focused portfolio of cannabis consumer brands and licensed supply relationships.
Key products and brands include pre-rolled marijuana cigarettes, or pre-rolls, as well as branded consumer offerings such as Fresh Joints, Doobskis, DutchBlunts, and Wee Joints. The company states that it owns, manufactures, and distributes these products to licensed marijuana dispensaries across Colorado. That operating model suggests a hybrid strategy: part branded consumer goods, part manufacturing and production services for retail partners. For a company of this size, that mix can be attractive because it combines direct brand-building with recurring production volume from dispensary clients.
From a competitive standpoint, Bespoke Extracts remains a small operator in a highly fragmented and intensely competitive cannabis industry. Its competitive advantages are likely to come from product quality, regulatory compliance, production reliability, and the ability to maintain relationships with licensed dispensaries. It is not a national multi-state operator; instead, it appears to be a Colorado-focused specialist with a narrower geographic footprint but potentially greater operational flexibility. That also means the company is exposed to sector-specific headwinds such as pricing pressure, compliance costs, and financing constraints that continue to affect cannabis businesses in the United States.
Geographically, the business is concentrated in Colorado, where production and distribution are based. Recent 2025 company disclosures highlighted a strategic rebranding under “The Joint Company,” alongside modest revenue growth, improved gross profit, and lower operating expenses in the first quarter of 2025. Taken together, those updates indicate a management focus on efficiency, branding, and execution rather than rapid geographic expansion. For French-speaking investors, Bespoke Extracts is best viewed as a highly speculative U.S. cannabis microcap in the Health & Pharma sector, with a narrow operating base, a local market focus, and an evolving but clearly defined product and distribution strategy.
Purchases our model currently ranks for the recommendations list.
All recommendations